Antigen News and Research RSS Feed - Antigen News and Research

New report on global peptide cancer therapeutics market

New report on global peptide cancer therapeutics market

Research and Markets has announced the addition of the "Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014" report to their offering. [More]
Widespread awareness, better treatment lower prostate cancer death rates

Widespread awareness, better treatment lower prostate cancer death rates

Fewer men are being diagnosed with and dying from prostate cancer these days. While that is due in part to widespread awareness and better treatment, it is also the result of more judicious screening. [More]
Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. [More]
TxCell announces five new patents for core technology and ASTrIA platform

TxCell announces five new patents for core technology and ASTrIA platform

TxCell SA, a biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, today announces that five new patents for their technologies have been issued in the Unites States, Asia and Australia since the beginning of 2014. [More]
Pathologists help determine prostate cancer patient’s eligibility for active surveillance

Pathologists help determine prostate cancer patient’s eligibility for active surveillance

Prostate cancer is the second leading cause of cancer death in men in the United States. Active surveillance offers low-risk prostate cancer patients a means to avoid the potentially harmful side effects from treatment. [More]
Viewpoints: Threat to drug development; GOP's Obamacare criticism tempered; finding doctors for seniors

Viewpoints: Threat to drug development; GOP's Obamacare criticism tempered; finding doctors for seniors

An invasive species has been introduced into the U.S. health innovation ecosystem, with a growing danger of permanent damage to the development of specialty drugs. [More]
Research finds stronger weapon against leprosy and tuberculosis

Research finds stronger weapon against leprosy and tuberculosis

In many parts of the world, leprosy and tuberculosis live side-by-side. Worldwide there are approximately 233,000 new cases of leprosy per year, with nearly all of them occurring where tuberculosis is endemic. [More]
Innate lymphoid cells induce specific T and B cell responses during inflammation

Innate lymphoid cells induce specific T and B cell responses during inflammation

In case of an inflammation the body releases substances that increase the immune defense. During chronic inflammation, this immune response gets out of control and can induce organ damage. [More]
BRCA2 mutations herald poor prognosis in screen-detected prostate cancer

BRCA2 mutations herald poor prognosis in screen-detected prostate cancer

Among men with prostate cancer detected on screening, survival among those with a mutation in the BRCA2 gene is much poorer than in those without such a mutation, researchers report. [More]
Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

The fungal infection invasive aspergillosis (IA) can be life threatening, especially in patients whose immune systems are weakened by chemotherapy or immunosuppressive drugs. Despite the critical need for early detection, IA remains difficult to diagnose. [More]
High-dose influenza vaccine 24% more effective in older adults

High-dose influenza vaccine 24% more effective in older adults

High-dose influenza vaccine is 24 percent more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness and its complications, according to a Vanderbilt-led study published today in the New England Journal of Medicine. [More]
MRI technology improves prostate cancer diagnosis

MRI technology improves prostate cancer diagnosis

Oncologists at UC San Diego Moores Cancer Center are the first in San Diego to meld magnetic resonance imaging (MRI) technology with a traditional ultrasound prostate exam to create a three-dimensional map of the prostate that allows physicians to view growths that were previously undetectable. [More]
Researchers develop novel fluorescence-based assay for early detection of diabetes

Researchers develop novel fluorescence-based assay for early detection of diabetes

A team of researchers from the Center for Engineering in Medicine at the Massachusetts General Hospital have developed a novel fluorescence-based assay for sensitive detection of antibodies within microliter volume serum samples. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™. [More]
EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union. [More]
Genticel provides update on patents granted in the USA and Asia

Genticel provides update on patents granted in the USA and Asia

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, provides an update on patents that have recently enriched its intellectual property estate. [More]
Immune system play role in memory impairment associated with chronic epilepsy

Immune system play role in memory impairment associated with chronic epilepsy

Could the body's own immune system play a role in memory impairment and cognitive dysfunction associated with conditions like chronic epilepsy, Alzheimer's dementia and concussions? Cleveland Clinic researchers believe so, based on a study published online by PLOS ONE. [More]

Prognostic value of visceral plural invasion limited in part-solid lung cancer

Visceral plural invasion is a significant predictor of survival in patients with small solid lung tumours but not in patients with part-solid tumours, Japanese study findings indicate. [More]
Iowa researchers develop vaccine to combat dust-mite allergies

Iowa researchers develop vaccine to combat dust-mite allergies

Researchers at the University of Iowa have developed a vaccine that can combat dust-mite allergies by naturally switching the body's immune response. [More]